Exelixis PI3K Interim Data (NASDAQ:EXEL)
Source: http://feedproxy.google.com/~r/FavStocks/~3/DJV0AGA6KhY/Posted on Wednesday, November 18th, 2009 | In Biotech, Investing Lessons, Stocks to Watch
Exelixis, Inc (NASDAQ:EXEL) has announced and reported that the interim data from an ongoing Phase 1 dose-escalation trial of XL147 (SAR245408) in combination with paclitaxel and carboplatin in patients with advanced solid tumors have displayed positive results.
XL147 is a selective, orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K). Exelixis has entered into a global license agreement with Sanofi-Aventis for XL147. Exelixis’ President of Research and Development, Michael M. Morrissey has mentioned that the preclinical data suggest that XL147 potentiates the antitumor efficacy of paclitaxel and carboplatin without exacerbating the toxicity of this commonly used regimen. Additionally, he also mentioned that they are very encouraged by this emerging signs of clinical activity and good tolerability of XL147 in combination with paclitaxel and carboplatin which will be used for the treatment of refractory patients with solid tumors.
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The Company has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, and other leading companies. Upregulation of PI3K activity is one of the most common characteristics of human tumor cells and can result from activation of growth factor receptors, mutational activation or amplification of the PI3K gene. The results of this study demonstrates the potential for enhancing anti-tumor activity by combining XL147 with two of the most commonly used chemotherapeutic agents available in the market.
Last 5 posts by Jyotsna Ramani
- ARCA Submits New SPA (NASDAQ:ABIO) - December 23rd, 2009
- ARCA Submits New SPA (NASDAQ:ABIO) - December 23rd, 2009
- Xcorporeal Signs Purchase Agreement (OTC:XCRP) - December 23rd, 2009
- Xcorporeal Signs Purchase Agreement (OTC:XCRP) - December 23rd, 2009
- Arrowhead Raises New Funds (NASDAQ:ARWR) - December 23rd, 2009
 About Jyotsna Ramani (http://www.favstocks.com)
Joyotsna has completed Post Graduation in Tourism from College of Vocational Studies apart from a full time MBA degree in Finance. She has worked with several reputed companies including IBM. Currently, she is a SAHM, earning a living off trading in the stock market and forex. |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.